Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
20
CARM Quote, Financials, Valuation and Earnings
Last price:
$0.04
Seasonality move
:
-21.27%
Day range:
$0.04 - $0.05
52-week range:
$0.03 - $1.27
Dividend yield:
0%
P/E ratio:
0.23x
P/S ratio:
0.03x
P/B ratio:
123.48x
Volume:
402.8K
Avg. volume:
452.5K
1-year change:
-89.69%
Market cap:
$1.8M
Revenue:
$19.6M
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CARM
Carisma Therapeutics, Inc.
|
-- | -$0.12 | -100% | -60.71% | $1.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CARM
Carisma Therapeutics, Inc.
|
$0.04 | $1.00 | $1.8M | 0.23x | $0.00 | 0% | 0.03x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $6.50 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $685.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CARM
Carisma Therapeutics, Inc.
|
-725.71% | 6.397 | 6.66% | 0.41x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CARM
Carisma Therapeutics, Inc.
|
-- | $43.8M | -437.23% | -437.23% | 96.83% | $1.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Carisma Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CARM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 98.82% compared to Carisma Therapeutics, Inc.'s net margin of -255.85%. Carisma Therapeutics, Inc.'s return on equity of -437.23% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CARMCarisma Therapeutics, Inc.-- $1.07 -$105K NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CARM or NBY?
Carisma Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 2220.19%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that Carisma Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Carisma Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CARMCarisma Therapeutics, Inc.0 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CARM or NBY More Risky?
Carisma Therapeutics, Inc. has a beta of 1.962, which suggesting that the stock is 96.202% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CARM or NBY?
Carisma Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Carisma Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARM or NBY?
Carisma Therapeutics, Inc. quarterly revenues are $45.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Carisma Therapeutics, Inc.'s net income of $44.7M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Carisma Therapeutics, Inc.'s price-to-earnings ratio is 0.23x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carisma Therapeutics, Inc. is 0.03x versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARMCarisma Therapeutics, Inc.0.03x 0.23x $45.3M $44.7M NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns CARM or NNVC?
NanoViricides, Inc. has a net margin of 98.82% compared to Carisma Therapeutics, Inc.'s net margin of --. Carisma Therapeutics, Inc.'s return on equity of -437.23% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital CARMCarisma Therapeutics, Inc.-- $1.07 -$105K NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About CARM or NNVC?
Carisma Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 2220.19%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 420%. Given that Carisma Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Carisma Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CARMCarisma Therapeutics, Inc.0 1 0 NNVCNanoViricides, Inc.1 0 0 -
Is CARM or NNVC More Risky?
Carisma Therapeutics, Inc. has a beta of 1.962, which suggesting that the stock is 96.202% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock CARM or NNVC?
Carisma Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carisma Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARM or NNVC?
Carisma Therapeutics, Inc. quarterly revenues are $45.3M, which are larger than NanoViricides, Inc. quarterly revenues of --. Carisma Therapeutics, Inc.'s net income of $44.7M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Carisma Therapeutics, Inc.'s price-to-earnings ratio is 0.23x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carisma Therapeutics, Inc. is 0.03x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARMCarisma Therapeutics, Inc.0.03x 0.23x $45.3M $44.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns CARM or OGEN?
Oragenics, Inc. has a net margin of 98.82% compared to Carisma Therapeutics, Inc.'s net margin of --. Carisma Therapeutics, Inc.'s return on equity of -437.23% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CARMCarisma Therapeutics, Inc.-- $1.07 -$105K OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CARM or OGEN?
Carisma Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 2220.19%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that Carisma Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Carisma Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CARMCarisma Therapeutics, Inc.0 1 0 OGENOragenics, Inc.1 0 0 -
Is CARM or OGEN More Risky?
Carisma Therapeutics, Inc. has a beta of 1.962, which suggesting that the stock is 96.202% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CARM or OGEN?
Carisma Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carisma Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARM or OGEN?
Carisma Therapeutics, Inc. quarterly revenues are $45.3M, which are larger than Oragenics, Inc. quarterly revenues of --. Carisma Therapeutics, Inc.'s net income of $44.7M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Carisma Therapeutics, Inc.'s price-to-earnings ratio is 0.23x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carisma Therapeutics, Inc. is 0.03x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARMCarisma Therapeutics, Inc.0.03x 0.23x $45.3M $44.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CARM or PTN?
Palatin Technologies has a net margin of 98.82% compared to Carisma Therapeutics, Inc.'s net margin of --. Carisma Therapeutics, Inc.'s return on equity of -437.23% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CARMCarisma Therapeutics, Inc.-- $1.07 -$105K PTNPalatin Technologies-- -- -- -
What do Analysts Say About CARM or PTN?
Carisma Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 2220.19%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Carisma Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Carisma Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CARMCarisma Therapeutics, Inc.0 1 0 PTNPalatin Technologies0 0 0 -
Is CARM or PTN More Risky?
Carisma Therapeutics, Inc. has a beta of 1.962, which suggesting that the stock is 96.202% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CARM or PTN?
Carisma Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carisma Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARM or PTN?
Carisma Therapeutics, Inc. quarterly revenues are $45.3M, which are larger than Palatin Technologies quarterly revenues of --. Carisma Therapeutics, Inc.'s net income of $44.7M is higher than Palatin Technologies's net income of --. Notably, Carisma Therapeutics, Inc.'s price-to-earnings ratio is 0.23x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carisma Therapeutics, Inc. is 0.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARMCarisma Therapeutics, Inc.0.03x 0.23x $45.3M $44.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CARM or TOVX?
Theriva Biologics, Inc. has a net margin of 98.82% compared to Carisma Therapeutics, Inc.'s net margin of --. Carisma Therapeutics, Inc.'s return on equity of -437.23% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CARMCarisma Therapeutics, Inc.-- $1.07 -$105K TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CARM or TOVX?
Carisma Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 2220.19%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Theriva Biologics, Inc. has higher upside potential than Carisma Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Carisma Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CARMCarisma Therapeutics, Inc.0 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CARM or TOVX More Risky?
Carisma Therapeutics, Inc. has a beta of 1.962, which suggesting that the stock is 96.202% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CARM or TOVX?
Carisma Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carisma Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARM or TOVX?
Carisma Therapeutics, Inc. quarterly revenues are $45.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Carisma Therapeutics, Inc.'s net income of $44.7M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Carisma Therapeutics, Inc.'s price-to-earnings ratio is 0.23x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carisma Therapeutics, Inc. is 0.03x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARMCarisma Therapeutics, Inc.0.03x 0.23x $45.3M $44.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
